IOVA
Iovance Biotherapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.87B
P/E Ratio
—
EPS
$-0.92
Beta
0.70
52W High
$5.63
52W Low
$1.66
50-Day MA
$3.72
200-Day MA
$2.93
Dividend Yield
—
Profit Margin
-123.90%
Forward P/E
—
PEG Ratio
0.00
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Fundamentals
| Revenue (TTM) | $285.61M |
| Gross Profit (TTM) | $112.64M |
| EBITDA | $-321.62M |
| Operating Margin | -113.50% |
| Return on Equity | -47.50% |
| Return on Assets | -23.60% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $1.65 |
| Price-to-Book | 2.45 |
| Price-to-Sales (TTM) | 6.54 |
| EV/Revenue | 5.26 |
| EV/EBITDA | -8.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 44.80% |
| Shares Outstanding | $446.50M |
| Float | $387.90M |
| % Insiders | 0.34% |
| % Institutions | 67.47% |
Historical Volatility
HV 10-Day
103.87%
HV 20-Day
88.23%
HV 30-Day
93.52%
HV 60-Day
82.78%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($8.80 target)
2
Strong Buy6
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026